<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069935</url>
  </required_header>
  <id_info>
    <org_study_id>FT538-102</org_study_id>
    <nct_id>NCT05069935</nct_id>
  </id_info>
  <brief_title>FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 dose-finding study of FT538 given in combination with a monoclonal antibody&#xD;
      following lymphodepletion in subjects with advanced solid tumors. The study will consist of a&#xD;
      dose-escalation stage and an expansion stage where participants will be enrolled into&#xD;
      indication-specific cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">August 5, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define RP2D</measure>
    <time_frame>1.5 years</time_frame>
    <description>To define the RP2D of FT538 in combination with the following mAbs in subjects with advanced solid tumors: avelumab, trastuzumab, cetuximab, atezolizumab, nivolumab, and pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature, and severity of AEs, with severity determined according to NCI CTCAE, v5.0</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the safety and tolerability of FT538 in combination with the following mAbs in subjects with advanced solid tumors: avelumab, trastuzumab, cetuximab, atezolizumab, nivolumab, and pembrolizumab</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">189</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved&#xD;
Cohort B: FT538 plus trastuzumab in subjects with advanced documented HER2+ tumors&#xD;
Cohort C: FT538 plus cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell carcinoma (HNSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A, Arm 1: FT538 plus avelumab in subjects with advanced solid tumors malignancies where anti-PD-1/PD-L1 antibodies are approved (except urothelial carcinoma (UC))&#xD;
Cohort A, Arm 2: FT538 plus an anti-PD-1 antibody (nivolumab or pembrolizumab) in subjects with solid tumor malignancies where anti-PD-1/PD-L1 antibodies are approved (except UC)&#xD;
Cohort B, Arm 1: FT538 plus trastuzumab in subjects with HER2+ tumors&#xD;
Cohort C, Arm 1: FT538 plus cetuximab in subjects with advanced CRC or HNSCC&#xD;
Subjects with UC may be enrolled in the randomized expansion cohorts as follows:&#xD;
Cohort A, Arm R1: FT538 plus avelumab&#xD;
Cohort A, Arm R2: FT538 plus atezolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT538</intervention_name>
    <description>FT538 is an allogeneic natural killer (NK)-cell immunotherapy</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
    <other_name>NK Cell Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
    <other_name>Cy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
    <other_name>Flu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Monoclonal antibody - Dose Escalation</intervention_name>
    <description>either avelumab, trastuzumab or cetuximab</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <other_name>mAb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Monoclonal antibody - Dose Expansion</intervention_name>
    <description>either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab</description>
    <arm_group_label>Dose Expansion</arm_group_label>
    <other_name>mAb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects with locally advanced or metastatic disease who have progressed after at least one&#xD;
        line of therapy and diagnosis of one of the following by treatment cohort:&#xD;
&#xD;
          -  Cohort A: The following solid tumor malignancies where anti-PD-1/PD-L1 antibodies are&#xD;
             approved: cutaneous melanoma, non-small cell/small cell lung cancer, renal cell&#xD;
             carcinoma, head and neck squamous cell cancer, microsatellite instability-high/&#xD;
             mismatch repair deficient cancer, gastric cancer, esophageal cancer, cervical cancer,&#xD;
             merkel cell carcinoma, endometrial carcinoma, tumor mutation burden-high ≥ 10&#xD;
             mutations/megabase], cutaneous squamous cell carcinoma, triple-negative breast cancer.&#xD;
&#xD;
          -  Cohort B: HER2+ breast cancer that has relapsed or progressed on trastuzumab and&#xD;
             progressed on either pertuzumab or HER2-targeting antibody drug conjugate; HER2+&#xD;
             gastric cancer that has relapsed or progressed on trastuzumab-containing therapy; OR&#xD;
             any other HER2+ solid tumor having progressed on at least one line of standard-of-care&#xD;
             therapy. For any tumor type in this cohort, HER2 status must be documented by a U.S.&#xD;
             Food and Administration (FDA) approved test to be ≥2+ IHC or Average HER2 copy number&#xD;
             ≥4 signals per cell by in situ hybridization.&#xD;
&#xD;
          -  Cohort C: CRC having progressed following prior cetuximab treatment or has KRAS/NRAS&#xD;
             mutation; HNSCC having progressed following prior cetuximab.&#xD;
&#xD;
        Capable of giving signed informed consent&#xD;
&#xD;
        Aged ~ 18 years old&#xD;
&#xD;
        Willingness to comply with study procedures and duration&#xD;
&#xD;
        Measurable disease per RECIST v1.1&#xD;
&#xD;
        For subjects with &gt;1 measurable lesion by RECIST v1.1 that can be safely accessed,&#xD;
        willingness to undergo tumor biopsy&#xD;
&#xD;
        Contraceptive use for women and men as defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant or breast-feeding women&#xD;
&#xD;
        ECOG performance status greater than or equal to 2&#xD;
&#xD;
        Evidence of insufficient organ function&#xD;
&#xD;
        Clinically significant cardiovascular disease including left-ventricular ejection fraction&#xD;
        &lt; 45%&#xD;
&#xD;
        Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter&#xD;
        or any investigational therapy within 28 days prior to Day 1&#xD;
&#xD;
        Known active central nervous system (CNS) involvement by malignancy that hasn'thas not&#xD;
        remained stable for at least 3 months following effective treatment for CNS disease&#xD;
&#xD;
        Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or neurodegenerative&#xD;
        disease or receipt of medications for these conditions&#xD;
&#xD;
        Currently receiving or likely to require immunosuppressive therapy Active bacterial,&#xD;
        fungal, or viral infections including hep B, Hep C or HIV Live vaccine within 6 weeks prior&#xD;
        to start of lympho-conditioning&#xD;
&#xD;
        Known allergy to albumin (human) or DMSO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Beagle</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DeShaun Noakes</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Albers</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-PD-1 / PD-L1 antibodies approved</keyword>
  <keyword>HER2+</keyword>
  <keyword>Metastatic CRC</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>NK Cells</keyword>
  <keyword>Urothelial Cancer</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>merkel cell carcinoma</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>immune checkpoint inhibitor</keyword>
  <keyword>melanoma, renal cell carcinoma, lung cancer,</keyword>
  <keyword>triple-negative breast cancer,</keyword>
  <keyword>head and neck squamous cell carcinoma,</keyword>
  <keyword>urothelial carcinoma (UC),</keyword>
  <keyword>Merkel cell carcinoma, squamous</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>gastric cancer, esophageal cancer, endometrial cancer,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

